Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPLATINUM phase 3 trial of RRx-001 followed by platinum doublet versus platinum doublet alone in third-line or later small cell lung cancer
CTR20221527Phase 3Active
- Sponsor
- 不适用/ 赛生医药（中国）有限公司
- Start
- Sep 2022
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Nibrozetone in small cell lung cancer (SCLC), sponsored by 不适用/ 赛生医药（中国）有限公司. Started Sep 2022; status: active.
02
Drugs
Nibrozetone
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20221527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221527.